Literature DB >> 18810766

Severe ulcerative colitis: at what point should we define resistance to steroids?

Maria Esteve1, Javier P Gisbert.   

Abstract

Corticosteroids are still the first-line treatment for active ulcerative colitis more than 50 years after the publication of trials assessing their beneficial effect, with about a 50% remission rate in cases of severe disease. The mortality related to severe attacks of ulcerative colitis has decreased dramatically, to less than 1%, in experienced centers, due to the appropriate use of intensive therapeutic measures (intravenous steroids, fluids and electrolytes, artificial nutritional support, antibiotics, etc), along with timely decision-making about second-line medical therapy and early identification of patients requiring colectomy. One of the most difficult decisions in the management of severe ulcerative colitis is knowing for how long corticosteroids should be administered before deciding that a patient is a non-responder. Studies assessing the outcome of acute attacks after steroid initiation have demonstrated that, in steroid-sensitive patients, the response generally occurs early on, in the first days of treatment. Different indexes to predict treatment failure, when applied on the third day of treatment, have demonstrated a high positive predictive value for colectomy. In contrast to this resolute approach, which is the most widely accepted, other authors have suggested that in some patients a complete and prolonged response to steroids may take longer. Either way, physicians taking care of these patients need to recognize that severe ulcerative colitis may be life-threatening, and they need to be careful with excessively prolonged medical treatment and delayed surgery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18810766      PMCID: PMC2746335          DOI: 10.3748/wjg.14.5504

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

1.  Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone.

Authors:  J H BARON; A M CONNELL; T G KANAGHINIS; J E LENNARD-JONES; A F JONES
Journal:  Br Med J       Date:  1962-08-18

2.  Cortisone in ulcerative colitis; preliminary report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1954-08-14

3.  ULCERATIVE COLITIS: A SURVEY OF NINETY-FIVE CASES.

Authors:  T L Hardy; E Bulmer
Journal:  Br Med J       Date:  1933-11-04

4.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

Review 5.  Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.

Authors:  Dan Turner; Catharine M Walsh; A Hillary Steinhart; Anne M Griffiths
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12-04       Impact factor: 11.382

6.  Prolonged medical therapy for severe pediatric ulcerative colitis.

Authors:  D M Gold; J J Levine; T A Weinstein; B Kessler; M J Pettei
Journal:  Am J Gastroenterol       Date:  1995-05       Impact factor: 10.864

7.  Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial.

Authors:  S Meyers; P K Lerer; E J Feuer; J W Johnson; H D Janowitz
Journal:  J Clin Gastroenterol       Date:  1987-02       Impact factor: 3.062

8.  Outcome of a conservative approach in severe ulcerative colitis.

Authors:  M Daperno; R Sostegni; N Scaglione; E Ercole; C Rigazio; R Rocca; A Pera
Journal:  Dig Liver Dis       Date:  2004-01       Impact factor: 4.088

9.  Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis.

Authors:  S C Lindgren; L M Flood; A F Kilander; R Löfberg; T B Persson; R I Sjödahl
Journal:  Eur J Gastroenterol Hepatol       Date:  1998-10       Impact factor: 2.566

10.  Prednisolone absorption in acute colitis.

Authors:  P R Elliott; J Powell-Tuck; P E Gillespie; J M Laidlow; J E Lennard-Jones; J English; J Chakraborty; V Marks
Journal:  Gut       Date:  1980-01       Impact factor: 23.059

View more
  2 in total

1.  Chinese research into severe ulcerative colitis has increased in quantity and complexity.

Authors:  Cheng-Xin Luo; Zhong-Hui Wen; Yu Zhen; Zhu-Jun Wang; Jing-Xi Mu; Min Zhu; Qin Ouyang; Hu Zhang
Journal:  World J Clin Cases       Date:  2018-03-16       Impact factor: 1.337

2.  Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration.

Authors:  Yiting Wang; Rupa Makadia; Christopher Knoll; Jill Hardin; Erica A Voss; Daniel Fife; Kourtney Davis; Sheldon Sloan
Journal:  BMC Gastroenterol       Date:  2021-03-17       Impact factor: 3.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.